VNDA News & Analysis

Vanda Pharmaceuticals (VNDA) Stock Rating Reiterated Buy by H.C. Wainwright

H.C. Wainwright has reiterated a Buy rating for Vanda Pharmaceuticals (VNDA). This reaffirmation comes amid ongoing evaluations of the company's stock performance. Analysts often monitor such ratings as indicators for potential market sentiment and investor confidence in the stock. The specific impact on VNDA's trading volume or price was not detailed, but maintaining a Buy rating usually suggests a positive outlook for investors.